BIOMAT Database Logo BIOMAT Database Logo

Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy. 2012

Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Cylene Pharmaceuticals, 5820 Nancy Ridge Drive, Suite 200, San Diego, CA 92121, USA.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D051573 Proto-Oncogene Proteins c-pim-1 Serine-threonine protein kinases that relay signals from CYTOKINE RECEPTORS and are involved in control of CELL GROWTH PROCESSES; CELL DIFFERENTIATION; and APOPTOSIS. c-pim-1 Protein,pim-1 Proto-Oncogene Protein,Pim-1 Kinase,Proto-Oncogene Protein c-pim-1,Proto-Oncogene Protein pim-1,Kinase, Pim-1,Pim 1 Kinase,Proto Oncogene Protein c pim 1,Proto Oncogene Protein pim 1,Proto Oncogene Proteins c pim 1,c pim 1 Protein,c-pim-1, Proto-Oncogene Protein,c-pim-1, Proto-Oncogene Proteins,pim 1 Proto Oncogene Protein,pim-1, Proto-Oncogene Protein

Related Publications

Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
January 2018, Anti-cancer agents in medicinal chemistry,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
June 2014, Molecular medicine reports,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Pim kinase inhibitors for the treatment of cancer and possibly more.
July 2014, ACS medicinal chemistry letters,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1.
June 2013, ChemMedChem,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
May 2017, Bioorganic & medicinal chemistry,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Potential for protein kinase C inhibitors in cancer therapy.
January 1995, Cancer treatment and research,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Novel Arcyriaflavin-A Derivatives as PIM Kinase Inhibitors for Treating Cancer.
January 2023, Anti-cancer agents in medicinal chemistry,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
November 2020, Bioorganic & medicinal chemistry,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
PIM kinase inhibitors: Structural and pharmacological perspectives.
June 2019, European journal of medicinal chemistry,
Denis Drygin, and Mustapha Haddach, and Fabrice Pierre, and David M Ryckman
Saccharomonosporine A inspiration; synthesis of potent analogues as potential PIM kinase inhibitors.
February 2020, RSC advances,
Copied contents to your clipboard!